Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 2196.HK Open Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in new tab
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Analysis (2196.HK)
Is Shanghai Fosun Pharmaceutical (Group) Co., Ltd. a good investment? Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) is currently trading at 18.63 HKD. Market analysts have a consensus price target of 30.53 HKD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 13.21. This relatively low multiple may signal that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is undervalued compared to historical market norms.
Earnings Schedule: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is expected to release its next earnings report on April 27, 2026. The market consensus estimate for Forward EPS is 1.38.
For income investors, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. pays a dividend yield of 1.88%. With a payout ratio of 26%, the dividend appears sustainable.
Investor FAQ
Does Shanghai Fosun Pharmaceutical (Group) Co., Ltd. pay a dividend?
Yes, it pays an annual dividend of 0.35 HKD (1.88% yield).
What asset class is Shanghai Fosun Pharmaceutical (Group) Co., Ltd.?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be April 27, 2026. The company currently has a trailing EPS of 1.41.
Company Profile
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetology respiratory health and professional medical products; oncology, neuroscience and other specialty fields; and solutions for infections, tumors, the central nervous system, and chronic diseases. In addition, the company offers online and offline medical services, such as pharmaceuticals and medical devices, consumer healthcare and special commodities; specialized medical disciplines; and insurance services. Further, it is involved in the import and export of medical equipment and the provision of related and other consulting services and investment management. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Dividend Yield
1.88% (5y avg: 2.17%)
Annual Dividends
0.35 HKD
Next ex. div date
July 24, 2025
Payout Ratio
25.81%
Historical Dividends
| Year | Total Dividends |
|---|---|
| 2026 | 0.33 HKD |
| Aug. 3, 2026 (estimated) | 0.3258 |
| 2025 | 0.35 HKD |
| Aug. 22, 2025 | 0.3500 |
| 2024 | 0.30 HKD |
| Aug. 23, 2024 | 0.3000 |
| 2023 | 0.46 HKD |
| Aug. 24, 2023 | 0.4600 |
| 2022 | 0.66 HKD |
| July 4, 2022 | 0.6600 |
| 2021 | 0.52 HKD |
| Aug. 3, 2021 | 0.5200 |
| 2020 | 0.43 HKD |
| Aug. 14, 2020 | 0.4300 |
| 2019 | 0.36 HKD |
| Aug. 16, 2019 | 0.3600 |
| 2018 | 0.46 HKD |
| Aug. 17, 2018 | 0.4599 |
| 2017 | 0.40 HKD |
| Aug. 24, 2017 | 0.4000 |
| 2016 | 0.32 HKD |
| June 14, 2016 | 0.3200 |
| 2015 | 0.36 HKD |
| Aug. 3, 2015 | 0.3550 |
| 2014 | 0.34 HKD |
| Aug. 8, 2014 | 0.3400 |
| 2013 | 0.21 HKD |
| July 4, 2013 | 0.2100 |
Yearly aggregated dividends
Dividends
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Aug 22, 2025 Paid
Dividend
0.35 HKD |
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion